Who Is Most at Risk for an “Eye Stroke” While Taking Ozempic?

Ozempic and other semaglutide drugs are now used by millions of people to manage diabetes and, increasingly, for weight loss. As use has expanded, so have reports of serious complications. One of the most alarming is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition often described as an “eye stroke.”

NAION involves a sudden loss of blood flow to the optic nerve, leading to partial or complete vision loss in one eye. The vision loss is often permanent. Patients may wake up with blurry vision, dark spots, or a “curtain” effect and have little warning beforehand. However, not everyone who takes Ozempic faces the same level of risk. Medical literature and emerging litigation point to certain patient characteristics that may increase susceptibility. Understanding who is most at risk is not just a medical issue; it also plays a central role in failure-to-warn lawsuits.

If you or a loved one were diagnosed with NAION during or after taking Ozempic in Brooklyn, the Bronx, Queens, or Manhattan, contact Leandros A. Vrionedes, P.C., to speak with an informed and dedicated New York City Ozempic injury lawyer.

What Is an “Eye Stroke”?

An eye stroke, or NAION, occurs when the blood supply to the optic nerve is reduced or interrupted. Unlike a typical stroke, it does not involve the brain, but the damage can be just as life-altering. NAION is usually painless, sudden, and irreversible. Many patients do not realize what has happened until they notice vision loss upon waking. Because it can look spontaneous, the role of medications is often not considered right away.

Age as a Risk Factor

Age is one of the most consistent risk factors for NAION. The condition is far more common in adults over 50. As people age, blood vessels naturally become less flexible, and circulation to small structures like the optic nerve can be more easily compromised.

Ozempic is frequently prescribed to middle-aged and older adults, especially those managing Type 2 diabetes. That overlap alone raises important questions about whether vision-related risks should have been more clearly disclosed to this population.

Diabetes and Blood Sugar Disorders

Diabetes is one of the strongest known risk factors for NAION. Chronically elevated blood sugar can damage blood vessels and impair circulation, including the tiny vessels that supply the optic nerve.

Many Ozempic users are diabetic or prediabetic. That means a large portion of the drug’s intended user base already falls into a higher-risk category for optic nerve injury. When a medication is marketed to patients with known vascular vulnerabilities, the importance of clear warnings becomes even more critical.

Vascular Risk Factors and Circulation Issues

NAION has long been associated with underlying vascular conditions. These include high blood pressure, high cholesterol, atherosclerosis, and other conditions that affect blood flow. Semaglutide drugs affect metabolic processes and can influence blood pressure, hydration, and circulation. Plaintiffs in current litigation allege that these effects may increase the likelihood of reduced blood flow to the optic nerve in vulnerable patients. When a drug interacts with known vascular risk factors, manufacturers are expected to consider whether that interaction creates a foreseeable risk of serious harm.

Sleep Apnea and Nighttime Blood Pressure Drops

Sleep apnea is another well-documented risk factor for NAION. People with sleep apnea experience repeated drops in oxygen levels during sleep, which can stress blood vessels and reduce oxygen delivery to the optic nerve. NAION often occurs overnight or upon waking. Some researchers believe that drops in nighttime blood pressure, combined with poor oxygenation, may play a role. Sleep apnea is common among individuals with obesity and Type 2 diabetes, the same populations frequently prescribed Ozempic. This overlap has become a point of concern in evaluating whether certain users face heightened and foreseeable risk.

Anatomical Susceptibility

Some people are born with a “crowded” optic nerve structure, sometimes referred to as a “disc at risk.” This anatomical feature makes the optic nerve more vulnerable to changes in blood flow. While patients may not know they have this condition until after vision loss occurs, manufacturers are expected to account for reasonably foreseeable vulnerabilities when a drug is prescribed to large populations.

Why Foreseeability Matters in Failure-to-Warn Claims

In drug injury cases, liability does not depend on whether a side effect happens to everyone. Instead, the key question is often foreseeability. If a manufacturer knows or should know that a medication may pose a serious risk to identifiable groups of patients, it has a duty to warn doctors and consumers. That duty is especially strong when the harm is severe, permanent, and life-altering, such as blindness.

In Ozempic-related NAION cases, plaintiffs argue that manufacturers failed to adequately warn about the risk of optic nerve injury, particularly for patients with diabetes, vascular disease, sleep apnea, or other known risk factors. The argument is not that every Ozempic user would suffer an eye stroke, but that the risk was predictable for certain users and was not properly disclosed.

Why These Claims Are Emerging Now

NAION is rare, and individual cases can be difficult to link to a medication at first. Over time, however, patterns emerge as more patients report similar injuries after using the same drug. As awareness grows among doctors, researchers, and patients, more people begin to question whether their vision loss was truly random or whether it could have been prevented with better warnings and information.

Legal Guidance After Vision Loss in New York

If you or a loved one has experienced sudden vision loss or an “eye stroke” after taking Ozempic or another semaglutide drug, it is important to have your situation reviewed by an attorney familiar with emerging drug litigation. At Leandros A. Vrionedes, P.C., we represent clients throughout New York City, Nassau County, and Westchester County in serious injury and product liability matters. We stay closely informed about developing claims involving Ozempic and NAION and can help evaluate whether a failure-to-warn claim may apply to your case.

Vision loss is permanent. The legal questions surrounding it deserve careful, informed attention. Call today for a free consultation.